NCT03323658View on ClinicalTrials.gov

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

August 3, 2021

Study Completion Date

March 25, 2022

Conditions
Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In SituInvasive Breast Carcinoma
Interventions
DRUG

Bexarotene

Given topically

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03323658 - Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer | Biotech Hunter | Biotech Hunter